Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cotinine is an alkaloid found in tobacco and the primary metabolite of nicotine, commonly used as a biomarker for tobacco smoke exposure. It acts pharmacologically by binding to and modulating neuronal nicotinic acetylcholine receptors (nAChRs) with much lower potency than nicotine. Cotinine may function as a positive allosteric modulator of α7 nicotinic acetylcholine receptors, facilitating endogenous neurotransmission without direct stimulation. It has demonstrated nootropic, antidepressant, anxiolytic, antipsychotic-like effects and potential benefits in animal models of depression, PTSD, schizophrenia, Alzheimer's disease, and Parkinson's disease. Cotinine fumarate was developed as an antidepressant under the brand name Scotine but was never marketed. Its half-life is approximately 20 hours in vivo making it useful for detecting tobacco exposure over several days.[1][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cotinine.